Christos Vaklavas

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Topics

Newly Diagnosed

Epidermal Growth Factor Receptor

Hematopoietic Stem Cell

Top Venues

Breast cancer research and treatment

Nature medicine

APL bioengineering

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo, Marie Davidian, Butch Tsiatis, Anne M Wallace, A Jo Chien, Erica Stringer-Reasor, Judy C Boughey, Coral Omene, Mariya Rozenblit, Kevin M Kalinsky, Anthony D Elias, Christos Vaklavas, Heather Beckwith, Nicole Williams, Mili Arora, Chaitali Nangia, Evanthia T Roussos Torres, Brittani Thomas, Kathy S Albain, Amy S Clark, Carla Falkson, Dawn L Hershman, Claudine Isaacs, Alexandra Thomas, Jennifer Tseng, Amy Sanford, Kay Yeung, Sarah Boles, Yunni Yi Chen, Laura Huppert, Nusrat Jahan, Catherine Parker, Karthik Giridhar, Frederick M Howard, M Michele Blackwood, Tara Sanft, Wen Li, Natsuko Onishi, Adam L Asare, Philip Beineke, Peter Norwood, Lamorna Brown Swigart, Gillian L Hirst, Jeffrey B Matthews, Brian Moore, William Fraser Symmans, Elissa Price, Diane Heditsian, Barbara LeStage, Jane Perlmutter, Paula R Pohlmann, Angela M DeMichele, Douglas Yee, Laura van 't Veer, Nola M Hylton, Laura J Esserman
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature medicine (2024)
Katia Khoury, Jane L Meisel, Christina Yau, Hope S Rugo, Rita Nanda, Marie Davidian, Butch Tsiatis, A Jo Chien, Anne M Wallace, Mili Arora, Mariya Rozenblit, Dawn L Hershman, Alexandra S Zimmer, Amy S Clark, Heather Beckwith, Anthony D Elias, Erica Stringer-Reasor, Judy C Boughey, Chaitali Nangia, Christos Vaklavas, Coral Omene, Kathy S Albain, Kevin M Kalinsky, Claudine Isaacs, Jennifer Tseng, Evanthia T Roussos Torres, Brittani Thomas, Alexandra Thomas, Amy Sanford, Ronald Balassanian, Cheryl Ewing, Kay Yeung, Candice A M Sauder, Tara Sanft, Lajos Pusztai, Meghna S Trivedi, Ashton Outhaythip, Wen Li, Natsuko Onishi, Adam L Asare, Philip Beineke, Peter Norwood, Lamorna Brown Swigart, Gillian L Hirst, Jeffrey B Matthews, Brian Moore, W Fraser Symmans, Elissa Price, Carolyn Beedle, Jane Perlmutter, Paula R Pohlmann, Rebecca A Shatsky, Angela M DeMichele, Douglas Yee, Laura van 't Veer, Nola M Hylton, Laura J Esserman
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nature medicine (2024)
Christos Vaklavas, Cindy B Matsen, Zhengtao Chu, Kenneth M Boucher, Sandra D Scherer, Satya Pathi, Anna Beck, Kirstyn E Brownson, Saundra S Buys, Namita Chittoria, Elyse D'Astous, H Evin Gulbahce, N Lynn Henry, Stephen M Kimani, Jane Porretta, Regina Rosenthal, John Ward, Mei Wei, Bryan E Welm, Alana L Welm
TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO precision oncology 8 (2024)
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li, Charles P Theuer, Edward P Acosta, Shi Wei, Eddy Shih-Hsin Yang, William E Grizzle, Andres Forero-Torres
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li, Charles P Theuer, Edward P Acosta, Shi Wei, Eddy Shih-Hsin Yang, William E Grizzle, Andres Forero-Torres
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li, Charles P Theuer, Edward P Acosta, Shi Wei, Eddy Shih-Hsin Yang, William E Grizzle, Andres Forero-Torres
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li, Charles P Theuer, Edward P Acosta, Shi Wei, Eddy Shih-Hsin Yang, William E Grizzle, Andres Forero-Torres
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li, Charles P Theuer, Edward P Acosta, Shi Wei, Eddy Shih-Hsin Yang, William E Grizzle, Andres Forero-Torres
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast cancer research and treatment 198 (2) (2023)
Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, Kevin J Ryan, Yufeng Li, Charles P Theuer, Edward P Acosta, Shi Wei, Eddy Shih-Hsin Yang, William E Grizzle, Andres Forero-Torres
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer. Breast cancer research and treatment (2023)
Bryan E Welm, Christos Vaklavas, Alana L Welm
Erratum: "Toward improved models of human cancer" [APL Bioeng. 5, 010901 (2021)]. APL bioengineering 5 (2) (2021)
Bryan E Welm, Christos Vaklavas, Alana L Welm
Toward improved models of human cancer. APL bioengineering 5 (1) (2021)
Adriana M Coletta, Mary C Playdon, Kelly G Baron, Mei Wei, Kristen Kelley, Christos Vaklavas, Anna Beck, Saundra S Buys, Jonathan Chipman, Cornelia M Ulrich, Darren Walker, Shelley White, Sonal Oza, Rebecca W Zingg, Pamela A Hansen
The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors. PloS one 16 (10) (2021)
Caitriona Cahir, Jeffrey P Leal, Lilja Solnes, Chiung-Yu Huang, Ashley Carpenter, Katy Gaffney, Vandana G Abramson, Lisa Anne Carey, Minetta C Liu, Mothaffar F Rimawi, Jennifer M Specht, Anna Maria V Storniolo, Vicente Valero, Christos Vaklavas, Ian E Krop, Eric P Winer, Melissa Camp, Robert S Miller, Antonio C Wolff, Ashley Cimino-Mathews, Ben Ho Park, Richard L Wahl, Vered Stearns
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (20) (2021)
Christos Vaklavas, Brian S Roberts, Katherine E Varley, Nancy U Lin, Minetta C Liu, Hope S Rugo, Shannon Puhalla, Rita Nanda, Anna Maria Storniolo, Lisa A Carey, Mansoor N Saleh, Yufeng Li, Jennifer F Delossantos, William E Grizzle, Albert F LoBuglio, Richard M Myers, Andres Forero-Torres, null null
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. Breast cancer research : BCR 22 (1) (2020)